SEC Filing Form 4: Dianthus Therapeutics, Inc. - Officer Transaction

On April 9, 2026, Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, Inc., executed a series of transactions involving the company's common stock. Savitz acquired 8,224 shares under a Rule 10b5-1 trading plan. Concurrently, Savitz disposed of 8,224 shares at a weighted average price of $89.84, with individual sale prices ranging from $89.75 to $89.95. Additionally, Savitz exercised a stock option to buy 8,224 shares, with the underlying shares vesting over four years starting January 1, 2024. Following these transactions, Savitz holds 71,776 shares of common stock, with the stock option still active.